PMID- 17465527
OWN - NLM
STAT- MEDLINE
DCOM- 20070806
LR  - 20181201
IS  - 8756-7938 (Print)
IS  - 1520-6033 (Linking)
VI  - 23
IP  - 3
DP  - 2007 May-Jun
TI  - A novel technique for loading of paclitaxel-PLGA nanoparticles onto ePTFE 
      vascular grafts.
PG  - 693-7
AB  - The major cause of hemodialysis vascular access dysfunction (HVAD) is the 
      occurrence of stenosis followed by thrombosis at venous anastomosis sites due to 
      the aggressive development of venous neointimal hyperplasia. Local delivery of 
      antiproliferative drugs may be effective in inhibiting hyperplasia without 
      causing systemic side effects. We have previously demonstrated that 
      paclitaxel-coated expanded poly(tetrafluoroethylene) (ePTFE) grafts, by a dipping 
      method, could prevent neointimal hyperplasia and stenosis of arteriovenous (AV) 
      hemodialysis grafts, especially at the graft-venous anastomoses; however, large 
      quntities of initial burst release have remained a problem. To achieve controlled 
      drug release, paclitaxel (Ptx)-loaded poly(lactic-co-glycolic acid) (PLGA) 
      nanoparticles (Ptx-PLGA-NPs) were prepared by the emulsion-solvent evaporation 
      method and then transferred to the luminal surface and inner part of ePTFE 
      vascular grafts through our micro tube pumping and spin penetration techniques. 
      Scanning electron microscope (SEM) images of various stages of Ptx-PLGA-NPs 
      unequivocally showed that micro tube pumping followed by spin penetration 
      effectively transferred Ptx-PLGA-NPs to the inner part, as well as the luminal 
      surface, of an ePTFE graft. In addition, the in vitro release profiles of 
      paclitaxel demonstrated that this new system achieved controlled drug delivery 
      with a reduced initial burst release. These results suggest that loading of 
      Ptx-PLGA-NPs to the luminal surface and the inner part of an ePTFE graft is a 
      promising strategy to ultimately inhibit the development of venous neointimal 
      hyperplasia.
FAU - Lim, Hyun Jung
AU  - Lim HJ
AD  - School of Chemistry and Molecular Engineering, Seoul National University, San 
      56-1, Shillim-dong, Gwanak-gu, Seoul 151-742, Korea.
FAU - Nam, Hye Yeong
AU  - Nam HY
FAU - Lee, Byung Ha
AU  - Lee BH
FAU - Kim, Dae Joong
AU  - Kim DJ
FAU - Ko, Jai Young
AU  - Ko JY
FAU - Park, Jong-Sang
AU  - Park JS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070428
PL  - United States
TA  - Biotechnol Prog
JT  - Biotechnology progress
JID - 8506292
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Polymers)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 9002-84-0 (Polytetrafluoroethylene)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Antineoplastic Agents, Phytogenic/administration & dosage/chemistry
MH  - *Blood Vessel Prosthesis
MH  - Drug Delivery Systems/methods
MH  - Humans
MH  - Lactic Acid/*chemistry
MH  - Microscopy, Electron, Scanning
MH  - Nanoparticles/*chemistry/ultrastructure
MH  - Nanotechnology/methods
MH  - Paclitaxel/administration & dosage/*chemistry
MH  - Particle Size
MH  - Polyglycolic Acid/*chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Polymers/*chemistry
MH  - Polytetrafluoroethylene/*chemistry
EDAT- 2007/05/01 09:00
MHDA- 2007/08/07 09:00
CRDT- 2007/05/01 09:00
PHST- 2007/05/01 09:00 [pubmed]
PHST- 2007/08/07 09:00 [medline]
PHST- 2007/05/01 09:00 [entrez]
AID - 10.1021/bp060338i [doi]
PST - ppublish
SO  - Biotechnol Prog. 2007 May-Jun;23(3):693-7. doi: 10.1021/bp060338i. Epub 2007 Apr 
      28.